# A Study in Chinese Patients With Acquired Blepharoptosis

> **NCT06683651** · PHASE3 · RECRUITING · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Blepharoptosis

## Interventions

- **DRUG:** STN1013800 ophthalmic solution
- **DRUG:** STN1013800 ophthalmic solution Liquid Base, without STN1013800

## Key facts

- **NCT ID:** NCT06683651
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683651, "A Study in Chinese Patients With Acquired Blepharoptosis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06683651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*